Clarus Therapeutics Holdings Profit Margin

The latest profit margin for CRXT is -304.7% as of June 2022. That compares with -41.22% in the prior-year period — down 639.2% year over year. That is below the sector sector average of 13.09%. Investors often review this figure alongside Clarus Therapeutics Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, CRXT's profit margin moved from -41.22% to -304.7% — a 639.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Clarus Therapeutics Holdings's valuation or profitability profile.

Against its sector companies, CRXT currently prints -304.7% for profit margin, while the sector average sits near 13.09%. That is roughly 2428.0% below the sector mean. Large gaps often invite a closer look at Clarus Therapeutics Holdings's growth, margins, and balance sheet.

Profit Margin shows how effectively Clarus Therapeutics Holdings converts resources into returns. At -304.7%, CRXT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -41.22% in the prior-year period — down 639.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CRXT's profit margin (-304.7%), review year-over-year change from -41.22%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.